Research programme: topical antiviral treatments - RxKinetix
Latest Information Update: 22 Feb 2008
At a glance
- Originator RxKinetix
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Viral infections
Most Recent Events
- 28 Jun 2002 Preclinical trials in Viral infections in USA (Topical)